問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

陳泱伊Chen, Yang-Yi
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

  • 1050556@kmuh.org.tw

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳泱伊

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Dermatology

List

7Cases

2021-08-31 - 2024-12-13

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2018-11-15 - 2020-12-31

Phase III

Completed
A Phase 3 Randomized Withdrawal, Double Blind, Placebo Controlled, Multi Center Study Investigating the Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over, with Moderate to Severe Atopic Dermatitis with the Option of Rescue Treatment in Flaring Subjects

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    PF-04965842

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2024-02-01 - 2028-03-01

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

2021-11-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-10-10 - 2027-07-14

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-05-01 - 2021-08-26

Phase II/III

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

  • Condition/Disease

    Alopecia Areata (AA)

  • Test Drug

    PF-06651600

Participate Sites
6Sites

Recruiting6Sites

2018-03-08 - 2021-07-04

Phase III

A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS

  • Condition/Disease

    Atopic dermatitis (AD)

  • Test Drug

    PF-04965842

Participate Sites
9Sites

Recruiting9Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB